Skip to main content
Erschienen in: Pathology & Oncology Research 2/2019

11.12.2018 | Original Article

Approach the Invasive Potential with Hurthle Cell Tumors of Thyroid

verfasst von: Li Ding, Yunhui Jiang, Wan Yang

Erschienen in: Pathology & Oncology Research | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

To observe the expression of P53, CyclinD1, Ki-67, Galectin-3, COX-2, Bcl-2 and approach their contribution on assessing the invasive potential for Hurthle cell tumors. Seventy-three cases of Hurthle cell tumor were collected for immunohistochemistry staining. The patients were followed up with 8 months to 5 years. Tumors were divided into four grades according to invasion and diameter:(1) extremely low risk (27 cases that less than 2 cm and without invasion), (2) low risk (18 cases that within 2–3.9 cm and without invasion), (3) moderate risk (21 cases that achieve 4 cm and without invasion), (4) high risk (7 cases that with invasion of capsule/vessel in spite of the diameter). Immunostaining presented that all 73 cases were positive with Galectin-3, COX-2 and Bcl-2. For each group, P53 positive were 29.6%, 55.6%, 90.5%, 100.0%; CyclinD1 stained with 7.4%,22.2%,52.4%,100.0% and Ki-67 were 0.0%,5.6%,9.5%,28.6%, respectively. The higher risk of tumor, the more cases that positive expressed P53 and CyclinD1. After following up within 49 patients, two of the recurring cases were positive with P53 and CyclinD1 and one of which was also highly expressed Ki-67. Detecting P53, CyclinD1 and Ki-67 might provide reference for invasive potential assessment with Hurthle cell tumors but not Galectin-3, COX-2 and Bcl-2.
Literatur
1.
Zurück zum Zitat Hoos A, Stojadinovic A, Singh B, Dudas ME, Leung DHY, Shaha AR, Shah JP, Brennan MF, Cordon-Cardo C, Ghossein R (2002) Clinical significance of molecular expressing profiles of Hurthle cell tumors of the thyroid gland analyzed via tissue microarrays [J]. Am J Pathol 160(1):175–183CrossRefPubMedPubMedCentral Hoos A, Stojadinovic A, Singh B, Dudas ME, Leung DHY, Shaha AR, Shah JP, Brennan MF, Cordon-Cardo C, Ghossein R (2002) Clinical significance of molecular expressing profiles of Hurthle cell tumors of the thyroid gland analyzed via tissue microarrays [J]. Am J Pathol 160(1):175–183CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Vogrin A, Besic H, Besic N, Music MM (2016) Recurrence rate in regional lymph nodes in 737 patients with follicular or Hürthle cell neoplasms [J]. Radiol Oncol 50(3):269–273CrossRefPubMedPubMedCentral Vogrin A, Besic H, Besic N, Music MM (2016) Recurrence rate in regional lymph nodes in 737 patients with follicular or Hürthle cell neoplasms [J]. Radiol Oncol 50(3):269–273CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Ahmadi S, Stang M, Jiang XS, Sosa JA (2016) Hürthle cell carcinoma: current perspectives [J]. Onco Targets and Therapy 9:6873–6884CrossRef Ahmadi S, Stang M, Jiang XS, Sosa JA (2016) Hürthle cell carcinoma: current perspectives [J]. Onco Targets and Therapy 9:6873–6884CrossRef
4.
Zurück zum Zitat Ernaga Lorea A, Migueliz Bermejo I, Anda Apinaniz E et al (2018) Comparison of clinical characteristics of patients with follicular thyroid carcinoma and Hürthle cell carcinoma [J]. Endocrinol Diabetes Nutr 65(3):136–142CrossRefPubMed Ernaga Lorea A, Migueliz Bermejo I, Anda Apinaniz E et al (2018) Comparison of clinical characteristics of patients with follicular thyroid carcinoma and Hürthle cell carcinoma [J]. Endocrinol Diabetes Nutr 65(3):136–142CrossRefPubMed
5.
Zurück zum Zitat Sippel RS, Elaraj DM, Khanafshar E, Zarnegar R, Kebebew E, Duh QY, Clark OH (2008) Tumor size predicts maligant potential in Hurthle cell neoplasms of the thyroid [J]. World J Surg 32(5):702–707CrossRefPubMed Sippel RS, Elaraj DM, Khanafshar E, Zarnegar R, Kebebew E, Duh QY, Clark OH (2008) Tumor size predicts maligant potential in Hurthle cell neoplasms of the thyroid [J]. World J Surg 32(5):702–707CrossRefPubMed
6.
Zurück zum Zitat Sugino K, Ito K, Mimura T, Kameyama K, Iwasaki H, Ito K (2001) Hurthle cell tumor of the thyroid: analysis of 188 cases [J]. World J Surg 25(9):1160–1163CrossRefPubMed Sugino K, Ito K, Mimura T, Kameyama K, Iwasaki H, Ito K (2001) Hurthle cell tumor of the thyroid: analysis of 188 cases [J]. World J Surg 25(9):1160–1163CrossRefPubMed
7.
Zurück zum Zitat Ding L, Zou X, Yang W et al (2016) Analyze two cases of encapsulated papillary oncocytic neoplasms (EPONs) of the thyroid [J]. Int J Clin Exp Pathol 9(7):7493–7497 Ding L, Zou X, Yang W et al (2016) Analyze two cases of encapsulated papillary oncocytic neoplasms (EPONs) of the thyroid [J]. Int J Clin Exp Pathol 9(7):7493–7497
8.
Zurück zum Zitat Ristevska N, Stojanoski S, Gjorceva DP (2015) Appearance of Hürthle cell carcinoma soon after surgical extirpation of Hürthle cell adenoma and follicular adenoma of the thyroid gland [J]. Radiol Oncol 49(1):26–31CrossRefPubMedPubMedCentral Ristevska N, Stojanoski S, Gjorceva DP (2015) Appearance of Hürthle cell carcinoma soon after surgical extirpation of Hürthle cell adenoma and follicular adenoma of the thyroid gland [J]. Radiol Oncol 49(1):26–31CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Chao TC, Lin JD, Chen MF (2005) Surgical treatment of Hurthle cell tumors of the thyroid [J]. World J Surg 29(2):164–168CrossRefPubMed Chao TC, Lin JD, Chen MF (2005) Surgical treatment of Hurthle cell tumors of the thyroid [J]. World J Surg 29(2):164–168CrossRefPubMed
10.
Zurück zum Zitat Besic N, Hocevar M, Zgajnar L et al (2006) Aggressiveness of therapy and prognosis of patients with Hurthle cell papillary thyroid carcinoma [J]. Thyroid 16(1):67–72CrossRefPubMed Besic N, Hocevar M, Zgajnar L et al (2006) Aggressiveness of therapy and prognosis of patients with Hurthle cell papillary thyroid carcinoma [J]. Thyroid 16(1):67–72CrossRefPubMed
11.
Zurück zum Zitat Anila KR, Nayak N, George PS, Jayasree K (2018) Cytomorphologic spectrum of Hurthle cell lesions of thyroid: a study of 54 cases [J]. Gulf J Oncolog 1(26):6–10PubMed Anila KR, Nayak N, George PS, Jayasree K (2018) Cytomorphologic spectrum of Hurthle cell lesions of thyroid: a study of 54 cases [J]. Gulf J Oncolog 1(26):6–10PubMed
12.
Zurück zum Zitat Krhin B, Goricar K, Gazic B, Dolzan V, Besic N (2016) Functional polymorphisms in antioxidant genes in Hurthle cell thyroid neoplasm - an association of GPX1 polymorphism and recurrent Hurthle cell thyroid carcinoma [J]. Radiol Oncol 50(3):289–296CrossRefPubMedPubMedCentral Krhin B, Goricar K, Gazic B, Dolzan V, Besic N (2016) Functional polymorphisms in antioxidant genes in Hurthle cell thyroid neoplasm - an association of GPX1 polymorphism and recurrent Hurthle cell thyroid carcinoma [J]. Radiol Oncol 50(3):289–296CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Zhang YW, Greenblatt DY, Repplinger D, Bargren A, Adler JT, Sippel RS, Chen H (2008) Older age and larger tumor size predict malignancy in hurthle cell neoplasms of the thyroid [J]. Ann Surg Oncol 15(10):2842–2846CrossRefPubMedPubMedCentral Zhang YW, Greenblatt DY, Repplinger D, Bargren A, Adler JT, Sippel RS, Chen H (2008) Older age and larger tumor size predict malignancy in hurthle cell neoplasms of the thyroid [J]. Ann Surg Oncol 15(10):2842–2846CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Ferreira-da-Silva A, Valacca C, Rios E, Pópulo H, Soares P, Sobrinho-Simões M, Scorrano L, Máximo V, Campello S (2015) Mitochondrial dynamics protein Drp1 is overexpressed in oncocytic thyroid tumors and regulates cancer cell migration [J]. PLoS One 10(3):e0122308CrossRefPubMedPubMedCentral Ferreira-da-Silva A, Valacca C, Rios E, Pópulo H, Soares P, Sobrinho-Simões M, Scorrano L, Máximo V, Campello S (2015) Mitochondrial dynamics protein Drp1 is overexpressed in oncocytic thyroid tumors and regulates cancer cell migration [J]. PLoS One 10(3):e0122308CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Petric R, Gazic B, Goricar K et al (2016) Expression of miRNA and occurrence of distant metastases in patients with Hurthle cell carcinoma [J]. Int J Endocrinol 8945247:2016 Petric R, Gazic B, Goricar K et al (2016) Expression of miRNA and occurrence of distant metastases in patients with Hurthle cell carcinoma [J]. Int J Endocrinol 8945247:2016
16.
Zurück zum Zitat Monaco M, Chiappetta G, Aiello C et al (2014) CBX7 expression in Oncocytic thyroid neoplastic lesions (Hürthle cell adenomas and carcinomas) [J]. Eur Thyroid J 3(4):211–216PubMedPubMedCentral Monaco M, Chiappetta G, Aiello C et al (2014) CBX7 expression in Oncocytic thyroid neoplastic lesions (Hürthle cell adenomas and carcinomas) [J]. Eur Thyroid J 3(4):211–216PubMedPubMedCentral
17.
Zurück zum Zitat Gopal RK, Kübler K, Calvo SE, Polak P, Livitz D, Rosebrock D, Sadow PM, Campbell B, Donovan SE, Amin S, Gigliotti BJ, Grabarek Z, Hess JM, Stewart C, Braunstein LZ, Arndt PF, Mordecai S, Shih AR, Chaves F, Zhan T, Lubitz CC, Kim J, Iafrate AJ, Wirth L, Parangi S, Leshchiner I, Daniels GH, Mootha VK, Dias-Santagata D, Getz G, McFadden DG (2018) Widespread chromosomal losses and mitochondrial DNA alterations as genetic drivers in Hürthle cell carcinoma [J]. Cancer Cell 34(2):242–255CrossRefPubMedPubMedCentral Gopal RK, Kübler K, Calvo SE, Polak P, Livitz D, Rosebrock D, Sadow PM, Campbell B, Donovan SE, Amin S, Gigliotti BJ, Grabarek Z, Hess JM, Stewart C, Braunstein LZ, Arndt PF, Mordecai S, Shih AR, Chaves F, Zhan T, Lubitz CC, Kim J, Iafrate AJ, Wirth L, Parangi S, Leshchiner I, Daniels GH, Mootha VK, Dias-Santagata D, Getz G, McFadden DG (2018) Widespread chromosomal losses and mitochondrial DNA alterations as genetic drivers in Hürthle cell carcinoma [J]. Cancer Cell 34(2):242–255CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Giaginis C, Alexandrou P, Delladetsima I, Karavokyros I, Danas E, Giagini A, Patsouris E, Theocharis S (2016) Clinical significance of Hu-antigen receptor (HuR) and cyclooxygenase-2 (COX-2) expression in human malignant and benign thyroid lesions [J]. Pathol Oncol Res 22(1):189–196CrossRefPubMed Giaginis C, Alexandrou P, Delladetsima I, Karavokyros I, Danas E, Giagini A, Patsouris E, Theocharis S (2016) Clinical significance of Hu-antigen receptor (HuR) and cyclooxygenase-2 (COX-2) expression in human malignant and benign thyroid lesions [J]. Pathol Oncol Res 22(1):189–196CrossRefPubMed
19.
Zurück zum Zitat Savin S, Cvejic D, Isic T, Petrovic I, Paunovic I, Tatic S, Havelka M (2006) Thyroid peroxidase immunohistochemistry in differential diagnosis of thyroid tumors [J]. Endocr Pathol 17(1):53–60CrossRefPubMed Savin S, Cvejic D, Isic T, Petrovic I, Paunovic I, Tatic S, Havelka M (2006) Thyroid peroxidase immunohistochemistry in differential diagnosis of thyroid tumors [J]. Endocr Pathol 17(1):53–60CrossRefPubMed
20.
Zurück zum Zitat Sumana BS, Shashidhar S, Shivarudrappa AS (2015) Galectin-3 immunohistochemical expression in thyroid neoplasms [J]. J Clin Diagn Res 9(11):EC07–EC11PubMedPubMedCentral Sumana BS, Shashidhar S, Shivarudrappa AS (2015) Galectin-3 immunohistochemical expression in thyroid neoplasms [J]. J Clin Diagn Res 9(11):EC07–EC11PubMedPubMedCentral
21.
Zurück zum Zitat Saleh HA, Jin B, Barnwell J, Alzohaili O (2010) Utility of immunohistochemical markers in differentiating benign from malignant follicular derived thyroid nodules [J]. Diagn Pathol 5:9CrossRefPubMedPubMedCentral Saleh HA, Jin B, Barnwell J, Alzohaili O (2010) Utility of immunohistochemical markers in differentiating benign from malignant follicular derived thyroid nodules [J]. Diagn Pathol 5:9CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Sun L, Wei X, Liu X, Zhou D, Hu F, Zeng Y, Sun Y, Luo S, Zhang Y, Yi XP (2016) Expression of prostaglandin E2 and EP receptors in human papillary thyroid carcinoma [J]. Tumour Biol 37(4):4689–4697CrossRefPubMed Sun L, Wei X, Liu X, Zhou D, Hu F, Zeng Y, Sun Y, Luo S, Zhang Y, Yi XP (2016) Expression of prostaglandin E2 and EP receptors in human papillary thyroid carcinoma [J]. Tumour Biol 37(4):4689–4697CrossRefPubMed
23.
Zurück zum Zitat Liang M, Zhao J (2018) Protein expressions of AIB1, p53 and Bcl-2 in epithelial ovarian cancer and their correlations with the clinical pathological features and prognosis [J]. Eur Rev Med Pharmacol Sci 22(16):5134–5139PubMed Liang M, Zhao J (2018) Protein expressions of AIB1, p53 and Bcl-2 in epithelial ovarian cancer and their correlations with the clinical pathological features and prognosis [J]. Eur Rev Med Pharmacol Sci 22(16):5134–5139PubMed
24.
Zurück zum Zitat Ru Y, Chen XJ, Zhao ZW, Zhang PF, Feng SH, Gao Q, Gao SG, Feng XS (2017) CyclinD1 and p57kip2 as biomarkers in differentiation, metastasis and prognosis of gastric cardia adenocarcinoma [J]. Oncotarget 8(43):73860–73870CrossRefPubMedPubMedCentral Ru Y, Chen XJ, Zhao ZW, Zhang PF, Feng SH, Gao Q, Gao SG, Feng XS (2017) CyclinD1 and p57kip2 as biomarkers in differentiation, metastasis and prognosis of gastric cardia adenocarcinoma [J]. Oncotarget 8(43):73860–73870CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Malmstrom PU, Hemdan T, Segersten U (2017) Validation of the ezrin, CK20, and Ki-67 as potential predictive markers for BCG instillation therapy of non-muscle-invasive bladder cancer [J]. Urol Oncol 35(8):532.e1–532.e6CrossRef Malmstrom PU, Hemdan T, Segersten U (2017) Validation of the ezrin, CK20, and Ki-67 as potential predictive markers for BCG instillation therapy of non-muscle-invasive bladder cancer [J]. Urol Oncol 35(8):532.e1–532.e6CrossRef
26.
Zurück zum Zitat Mu N, Juhlin CC, Tani E, Sofiadis A, Reihnér E, Zedenius J, Larsson C, Nilsson IL (2018) High Ki-67 index in fine needle aspiration cytology of follicular thyroid tumors is associated with increased risk of carcinoma [J]. Endocrine 61(2):293–302CrossRefPubMedPubMedCentral Mu N, Juhlin CC, Tani E, Sofiadis A, Reihnér E, Zedenius J, Larsson C, Nilsson IL (2018) High Ki-67 index in fine needle aspiration cytology of follicular thyroid tumors is associated with increased risk of carcinoma [J]. Endocrine 61(2):293–302CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Erickson LA, Jin L, Goellner JR, Lohse C, Pankratz VS, Zukerberg LR, Thompson GB, van Heerden JA, Grant CS, Lloyd RV (2000) Pathologic features, proliferative activity, and CyclinD1 expression in Hurthle cell neoplasms of the thyroid [J]. Mod Pathol 13(2):186–192CrossRefPubMed Erickson LA, Jin L, Goellner JR, Lohse C, Pankratz VS, Zukerberg LR, Thompson GB, van Heerden JA, Grant CS, Lloyd RV (2000) Pathologic features, proliferative activity, and CyclinD1 expression in Hurthle cell neoplasms of the thyroid [J]. Mod Pathol 13(2):186–192CrossRefPubMed
Metadaten
Titel
Approach the Invasive Potential with Hurthle Cell Tumors of Thyroid
verfasst von
Li Ding
Yunhui Jiang
Wan Yang
Publikationsdatum
11.12.2018
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 2/2019
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-018-0546-x

Weitere Artikel der Ausgabe 2/2019

Pathology & Oncology Research 2/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.